Eris Lifesciences Ltd. Share Price

GIFT NIFTY SIGNALS SHARP GAP-DOWN | FIIs BUY ₹4,240 CRORE..

PRE-MARKET REPORT | 28 OCTOBER 2026 GIFT NIFTY SIGNALS SHARP GAP-DOWN | FIIs BUY ₹4,240 CRORE | BANK NIFTY SUPPORT AT 53,700–54,000 Market Outlook: Cautious Opening | Stock-Specific Opportunities | Watch Crude Oil and Key Support Levels Indian markets may open under pressure on Wednesday as elevated crude oil prices and uncertainty ahead of the US Federal Reserve’s policy decision weigh on sentiment. However, strong FII buying in the previous session and positive corporate results could support selective stocks. The key question for today is whether buyers defend the Bank Nifty support zone of 53,700–54,000 and help the market recover after a weak opening. ---> FII–DII DATA | 27 OCTOBER 2026 Institutional flows showed strong foreign buying, offset partly by domestic institutional selling. Institutional Activity Net Flow (₹ Crore) FII Cash Market +4,240.39 DII Cash Market -1,250.03 FII Stock Futures +3,160.84 FII Stock Options +383.47 --->BANK NIFTY: 53,700–54,000 IS THE KEY SUPPORT ZONE Bank Nifty is approaching an important demand area, with the 53,700–54,000 range likely to be crucial for intraday sentiment. Level Trading Significance 54,000 First level to reclaim for signs of recovery 53,700–54,000 Key support and potential buying-interest zone 54,200 Initial resistance reference 54,400–54,450 -->

: STRONG Q2 RESULTS Tata Capital reported encouraging Q2 FY27 results, with consolidated net profit rising 51% year-on-year to ₹1,660 crore. --->BROKERAGE ACTIONS: STOCKS IN FOCUS Supreme Industries — Target Price Cut Dalmia Bharat — Multiple Brokerages Cut Targets Urban Company — Positive Brokerage View Eris Lifesciences — Brokerage Views Need Careful Reading --->THE BOTTOM LINE The market opens with conflicting signals: strong FII cash buying and higher US markets on one side, elevated crude oil prices and a weak GIFT Nifty indication on the other.

See More

ERIS LIFESCIENCES: DOMESTIC PHARMA GROWTH IN FOCUS

is on the watchlist ahead of its September-quarter results. The company operates in the Indian pharmaceutical market, where performance depends on prescription demand, product mix, pricing, distribution and the ability to expand its portfolio. Key points to monitor: - Revenue growth across therapy areas - Operating margins - Product launches and portfolio expansion - Marketing and distribution expenses - Management outlook for the second half of the financial year My view: Revenue growth becomes more meaningful when accompanied by healthy margins and sustainable demand. Investors should look for evidence of execution and earnings quality in the latest results. The market’s reaction will depend on reported performance, expectations and forward guidance. Disclosure: This note represents my independent research assessment. I do not hold this stock. This is for informational purposes and should not be considered a recommendation to buy or sell.

See More

Title (60 chars): Eris Lifesciences Q1 FY27: GLP-1 leader

Eris Lifesciences Limited reported Q1 FY27 results for the June 2026 quarter on 29 July. Revenue grew 13% and profit 14.5%, but the EBITDA margin missed guidance. Q1 FY27 numbers (consolidated): Revenue: Rs 873.25 crore, up 13% YoY from Rs 771.56 crore EBITDA: Rs 296 crore, up 7% YoY; margin 33.9% vs FY27 guidance 36 to 37% PAT: Rs 142.39 crore, up 14.5% YoY from Rs 125.10 crore; EPS Rs 10.28 DBF segment: up 14.2%; 7 of 10 therapies in double digits Semaglutide (GLP-1): 20% volume share, 14% value share; ranked first in generic semaglutide prescriptions Interim dividend Rs 7.21 per share The margin miss is structural. Biologics and insulin carry lower initial gross margins than legacy oral anti-diabetes; as they scale, margins are expected to recover. HALMED inspection findings from March 2026 have delayed European CDMO commercialisation. Eris Lifesciences [][***** shares closed at Rs 1,288.21 (18 Sep 2026, 03:29 PM IST), down 23 percent over one year, near the Rs 1,222 52-week low. P/E 27.6; sector P/E 44.64; PEG 0.38. My view: the GLP-1 thesis is intact — number-one rank in generic semaglutide prescriptions in the launch quarter. The issue is that biologics compress margins in the near term and HALMED delays the EU CDMO revenue that was part of the FY27 thesis. At 27.6x, PEG 0.38 vs sector 44x, the compressed multiple is either an opportunity or an early signal of structural margin pressure. FY27 margin exit rate is the test. Accumulate Rs 1,222 to 1,290; invalidation on a close below Rs 1,222; Rs 1,450 to 1,500 the resistance. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.

See More

WATCH OUT FOR CORPORATE ACTIONS

Watch out for the Corporate actions today 29-May-2026 on the below mentioned stocks: - Life Insurance Corporation of India (LIC) : - Life Insurance Corporation of India 1:1 Bonus Issue (Investors receive 1 free additional share for every 1 share held). The Ex-Date and Record Date are both fixed for May 29, 2026. Bajaj Auto Ltd, GlaxoSmithKline Pharma, Torrent Pharmaceuticals, ERIS Lifesciences Ltd, ICICI Lombard GI, Home First Finance, and Bank of India will trade Ex-Dividend tomorrow the 29-May-2026.

See More

Earnings Alert: Stocks in Focus Ahead of Q4 Announcements

📊 Q4 Results Watch | Earnings Announcement Today Investors and market participants will closely track Q4 earnings today from: •

• • • • • !Dr Agarwals Eye Hospital • • • • • • • Key management commentary on margins, demand outlook, capex, and FY27 guidance will remain in focus. Stay alert for earnings-driven volatility and sector-specific opportunities across the market. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

Swing Bullish Strategy – Eagle Momentum (Weekly)

Swing Bullish Strategy – Eagle Momentum (Weekly)

has been outperformed Nifty 500 over last 1 week. The Weekly Eagle Momentum strategy focuses on identifying stocks showing strong short-term relative strength compared to the broader market. It selects stocks that have outperformed the benchmark over the last 1 week, indicating strong buying interest and emerging momentum. Traders use this strategy to identify stocks that may continue their short-term upward momentum, making them suitable candidates for swing trades. Traders typically combine this with price structure, volume strength, and support levels to identify potential entries while maintaining disciplined risk management. Disclaimer - Investments in securities market are subject to market risks, read all the related documents carefully before investing.

See More